Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis

Rhodes, Jonathan M.; Robinson, Richard; Beales, Ian; Pugh, S.; Dickinson, Rebecca; Dronfield, M W; Speirs, C. J.; Wilkinson, P.; Wilkinson, S. P.

doi:10.1111/j.1365-2036.2007.03569.x

Cited by 32 publications

(26 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prednisolone metasulphobenzoate is used for the treatment of ulcerative colitis and can be administered as an oral controlledrelease formulation (Predocol, Enterotech Limited, Jersey, UK) [Rhodes et al 2008 [Rhodes et al 2008]. Prednisolone metasulphobenzoate was also shown to be associated with significantly fewer glucocorticosteroid-associated adverse events than the tapered prednisolone regimen (Table 2).…”

Section: Prednisolone Metasulphobenzoatementioning

confidence: 99%

Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity

Prantera

Marconi

2013

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are a group of inflammatory conditions characterized by chronic, uncontrolled inflammation of the gastrointestinal tract. Reported prevalence is high in the United States and northern Europe, while the incidence varies greatly across the rest of Europe. Glucocorticosteroids are the standard treatment for IBD, but due to adverse events their use can be limited. However, new formulations of glucocorticosteroids have been developed to reduce systemic activation. The aim of this review was to assess and summarize the efficacy and safety of new formulations of glucocorticosteroids. A MEDLINE search identified publications focused on new formulations of nonsystemic steroidbased drugs for IBD and benefits and limitations of each of the new glucocorticosteroid formulations were identified. Budesonide has good efficacy and is an established treatment for Crohn's disease; it has been shown to be beneficial for the induction of remission in these patients, although it is not recommended for the maintenance of induced remission. Glucocorticosteroids are not recommended for the maintenance of remission in patients with IBD. However, a recent study suggested that beclomethasone dipropionate may be effective for prolonged treatment in patients in the postacute phase of Crohn's disease who were treated with a short course of systemic steroids. The efficacy of fluticasone propionate and prednisolone metasulphobenzoate in IBD is not well established given the small number of patients enrolled in the few published clinical trials. While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted.

show abstract

Section: Prednisolone Metasulphobenzoatementioning

confidence: 99%

Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity

Prantera

Marconi

2013

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…At 2 months, patients taking Predocol perceived less marked steroid-related side effects than those taking prednisolone. Overall, effi cacy was similar although there were signals that Predocol may have been less effective than prednisolone [31].…”

Section: Corticosteroidsmentioning

confidence: 91%

Optimizing conventional therapies for inflammatory bowel disease

Sparrow

Irving²,

Hanauer

2009

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Conventional therapies remain the mainstay of treatment for most patients with inflammatory bowel disease (IBD), with only a minority of patients requiring biologic therapies. Recently, attention has focused on optimizing dosing strategies for biologic agents; however, of equal importance are recent advances in the optimization of conventional IBD therapies. Newer aminosalicylate formulations demonstrate similar efficacy with a reduced pill burden and less frequent dosing, while new corticosteroid preparations may retain efficacy with a significantly improved safety profile. The limited indications for antibiotics and probiotics have been further refined by recent data, although uncertainties remain. Advances in the understanding of thiopurine metabolism continue to improve dose optimization and the potential for deliberate therapeutic manipulation with adjunctive therapies. An improved knowledge of intracellular methotrexate metabolism may translate to similar opportunities in the future. This article discusses recent advances relevant to clinical practice today.

show abstract

“…Remission rates at 6 months also did not differ significantly between the treatment arms. Predocol 40 mg/day had markedly fewer side effects than a conventional tapering prednisolone regimen 54 …”

Section: Corticosteroidsmentioning

confidence: 95%

Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis

Kamm

2008

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Treatment options for ulcerative colitis (UC) are expanding with the development of novel drug formulations and dosing regimens and new chemical entities. Although the goals of medical therapy for UC remain unchanged, that is to induce and to maintain remission, focus has also centred on improving patient compliance, modifying the natural course of disease and healing the mucosa. Aim To examine novel formulations, new chemical entities and novel therapeutic approaches to the management of UC. Methods Searches for all studies related to UC treatment in Medline and abstracts from major national and international meetings published in the last 10 years. Results 5‐Aminosalicylic acids (5‐ASA) remain the standard first‐line treatment for patients with mild to moderately active UC. New formulations with altered delivery, and new dosing regimens have demonstrated possible improvements in efficacy compared with historically available preparations and dosing patterns. Once‐daily dosing, micropellet formulations, and high‐dose tablets offer enhanced efficacy and improved compliance. 5‐ASA is now recognized as a ligand for peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) and it has a role as a chemo‐preventive agent in long‐standing UC. New colonic release corticosteroid formulations help to limit systemic toxicity; turmeric, tacrolimus and infliximab have shown promising results. New anti‐inflammatory targeted therapies include an anti‐CD3 antibody, selective integrin blockers, anti‐IL‐2 antibody and PPAR‐γ agonists. Conclusion The evolution of novel oral 5‐ASA formulations and dosage regimens, and recent development of new molecules have expanded the therapeutic armamentarium of UC.

show abstract

Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis

Abstract: SUMMARY BackgroundSystemic corticosteroids are effective in ulcerative colitis but commonly cause side effects.

Cited by 32 publications

References 29 publications

Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity

Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity

Optimizing conventional therapies for inflammatory bowel disease

Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis

Contact Info

Product

Resources

About